Overall survival (OS) analysis of all cancer types pooled together demonstrated a worse prognosis for cases with LRRK2 alterations (207/613 deceased, median OS: 94.03 months) in comparison to cases with unaltered LRRK2 (4123/11,356 deceased, median OS: 103.26 months) as shown in Figure 4; this result was statistically significant, with p = 0.0280. The gene discussed is LRRK2; the disease is cancer.